169 related articles for article (PubMed ID: 18644133)
1. Gastrointestinal (GI)-Specific patient reported outcomes instruments differentiate between renal transplant patients with or without GI symptoms: results from a South American cohort.
Machnicki G; Pefaur J; Gaite L; Linchenco AM; Raimondi C; Schiavelli R; Otero A; Margolis MK
Health Qual Life Outcomes; 2008 Jul; 6():53. PubMed ID: 18644133
[TBL] [Abstract][Full Text] [Related]
2. Using GI-specific patient outcome measures in renal transplant patients: validation of the GSRS and GIQLI.
Kleinman L; Kilburg A; Machnicki G; Faull R; Walker R; Prasad R; Ambuehl P; Bahner U; Margolis MK
Qual Life Res; 2006 Sep; 15(7):1223-32. PubMed ID: 16972162
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal-specific patient-reported outcome instruments differentiate between renal transplant patients with or without GI complications.
Kleinman L; Faull R; Walker R; Ramesh Prasad GV; Ambuehl P; Bahner U
Transplant Proc; 2005 Mar; 37(2):846-9. PubMed ID: 15848552
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Chan L; Mulgaonkar S; Walker R; Arns W; Ambühl P; Schiavelli R
Transplantation; 2006 May; 81(9):1290-7. PubMed ID: 16699457
[TBL] [Abstract][Full Text] [Related]
5. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
Hwang HS; Hyoung BJ; Kim S; Oh HY; Kim YS; Kim JK; Kim YH; Kim YL; Kim CD; Shin GT; Yang CW
J Korean Med Sci; 2010 Dec; 25(12):1759-65. PubMed ID: 21165291
[TBL] [Abstract][Full Text] [Related]
6. Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients.
Sterneck M; Settmacher U; Ganten T; Sarrazin C; Speidel N; Broering D; Heyne N; Paulus E; Mertens M; Fischer L
Transplant Proc; 2014; 46(1):234-40. PubMed ID: 24507058
[TBL] [Abstract][Full Text] [Related]
7. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
Darji P; Vijayaraghavan R; Thiagarajan CM; Sharma RK; Subbarao B; Pishardy R; Dakshinamurthy KV; Vijaykumar R; Abraham G; Bhaskar S; Agarwal L; Shah B; Abraham A; John M; Sampathkumar K; Das T; Umesh L; Sundar S; Ballal H; Jasuja S; Saxena S; Saha TK
Transplant Proc; 2008 Sep; 40(7):2262-7. PubMed ID: 18790208
[TBL] [Abstract][Full Text] [Related]
8. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease.
Revicki DA; Wood M; Wiklund I; Crawley J
Qual Life Res; 1998 Jan; 7(1):75-83. PubMed ID: 9481153
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal symptoms impair quality of life in Italian renal transplant recipients but are under-recognized by physicians.
Ponticelli C; Colombo D; Novara M; Basilisco G;
Transpl Int; 2010 Nov; 23(11):1126-34. PubMed ID: 20525020
[TBL] [Abstract][Full Text] [Related]
10. Improvement of gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients.
Toledo AH; Hendrix L; Buchholz V; Fisher E; Newton K; Smith C; Gerber DA
Clin Transplant; 2012; 26(1):156-63. PubMed ID: 21470310
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
[TBL] [Abstract][Full Text] [Related]
12. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients.
Bolin P; Tanriover B; Zibari GB; Lynn ML; Pirsch JD; Chan L; Cooper M; Langone AJ; Tomlanovich SJ
Transplantation; 2007 Dec; 84(11):1443-51. PubMed ID: 18091520
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.
Yang JW; Lee PH; Hutchinson IV; Pravica V; Shah T; Min DI
Ther Drug Monit; 2009 Oct; 31(5):542-8. PubMed ID: 19730281
[TBL] [Abstract][Full Text] [Related]
14. [Psychometric validation of the Polish translation of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) Questionnaire in patients with reflux disease].
Kulich KR; Reguła J; Stasiewicz J; Jasinski B; Carlsson J; Wiklund I
Pol Arch Med Wewn; 2005 Mar; 113(3):241-9. PubMed ID: 16128281
[TBL] [Abstract][Full Text] [Related]
15. Psychometric validation of the Hungarian translation of the gastrointestinal symptom rating scale (GSRS) and quality of life in reflux and dyspepsia (QOLRAD) questionnaire in patients with reflux disease.
Kulich RK; Ujszászy L; Tóth GT; Bárány L; Carlsson J; Wiklund I
Orv Hetil; 2004 Mar; 145(13 Suppl 2):723-9, 739-44. PubMed ID: 15125325
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a specific questionnaire for evaluating the impact of gastrointestinal symptoms on the health-related quality of life of transplant patients.
Ortega F; Bravo J; Cantarell C; Cofán F; Gómez-Bravo MA; Miras M; Crespo-Leiro MG; Ussetti P; Guinea G
Transplant Proc; 2012 Jun; 44(5):1281-6. PubMed ID: 22664001
[TBL] [Abstract][Full Text] [Related]
17. Psychometric validation of the German translation of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in patients with reflux disease.
Kulich KR; Malfertheiner P; Madisch A; Labenz J; Bayerdörffer E; Miehlke S; Carlsson J; Wiklund IK
Health Qual Life Outcomes; 2003 Oct; 1():62. PubMed ID: 14613560
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil.
Lopez-Solis R; DeVera M; Steel J; Fedorek S; Sturdevant M; Hughes C; Humar A
Clin Transplant; 2014 Jul; 28(7):783-8. PubMed ID: 24754682
[TBL] [Abstract][Full Text] [Related]
19. Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study.
Kulich KR; Madisch A; Pacini F; Piqué JM; Regula J; Van Rensburg CJ; Ujszászy L; Carlsson J; Halling K; Wiklund IK
Health Qual Life Outcomes; 2008 Jan; 6():12. PubMed ID: 18237386
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Cofan F; Rosich E; Arias M; Torregrosa V; Oppenheimer F; Campistol JM
Transplant Proc; 2007 Sep; 39(7):2179-81. PubMed ID: 17889130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
